Trial reportBMC veterinary research2015
Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves.
Trial report in BMC veterinary research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- Effect of a spore-based Mannheimia haemolytica vaccine on immune responses and respiratory microbiota in sheep.NPJ vaccines · 2026Article
- A novel nanoparticle vaccine, based on S1-CTD, elicits robust protective immune responses against porcine deltacoronavirus.Journal of virology · 2025Article
- PLGA-Based Strategies for Intranasal and Pulmonary Applications.Pharmaceutics · 2025Review
- Novel BPI3Vc-vectored surface displayed fusion and hemagglutinin-neuraminidase antigens elicit broadly neutralizing antibodies in cattle.Frontiers in immunology · 2025Article
- Local and systemic humoral immune responses to Histophilus somni recombinant antigens administered intranasally and subcutaneously to dairy calves.Scientific reports · 2024Article
- Meeting Contemporary Challenges: Development of Nanomaterials for Veterinary Medicine.Pharmaceutics · 2023Review
- Perspective vaccines for emerging viral diseases in farm animals.Clinical and experimental vaccine research · 2023Review
- The combination of vaccines and adjuvants to prevent the occurrence of high incidence of infectious diseases in bovine.Frontiers in veterinary science · 2023Review
- SARS-CoV-2 and its new variants: a comprehensive review on nanotechnological application insights into potential approaches.Applied nanoscience · 2023Review
- Polymeric Nanoparticles for Inhaled Vaccines.Polymers · 2022Review
- Polylactide Perspectives in Biomedicine: From Novel Synthesis to the Application Performance.Pharmaceutics · 2022Review
- Review
- Polymeric Materials as Potential Inhibitors Against SARS-CoV-2.Journal of polymers and the environment · 2022Review
- Review
- Nanoparticles as a novel and promising antiviral platform in veterinary medicine.Archives of virology · 2021Review
- Review on bovine respiratory syncytial virus and bovine parainfluenza - usual suspects in bovine respiratory disease - a narrative review.BMC veterinary research · 2021Review
- Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID).International journal of molecular sciences · 2021Review
- Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics.Nanomedicine (London, England) · 2021Review
- Nanotechnology against the novel coronavirus (severe acute respiratory syndrome coronavirus 2): diagnosis, treatment, therapy and future perspectives.Nanomedicine (London, England) · 2021Review
- Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses.PPAR research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a need to improve vaccination against respiratory pathogens in calves by stimulation of local immunity at the site of pathogen entry at an early stage in life. Ideally such a vaccine preparation would not be inhibited by the maternally derived antibodies. Additionally, localized immune response at the site of infection is also crucial to control infection at the site of entry of virus. The present study investigated the response to an intranasal bovine parainfluenza 3 virus (BPI3V) antigen preparation encapsulated in PLGA (poly dl-lactic-co-glycolide) nanoparticles in the presence of pre-existing anti-BPI3V antibodies in young calves and comparing it to a commercially available BPI3V respiratory vaccine.
resultsThere was a significant (P < 0.05) increase in BPI3V-specific IgA in the nasal mucus of the BPI3V nanoparticle vaccine group alone. Following administration of the nanoparticle vaccine an early immune response was induced that continued to grow until the end of study and was not observed in the other treatment groups. Virus specific serum IgG response to both the nanoparticle vaccine and commercial live attenuated vaccine showed a significant (P < 0.05) rise over the period of study. However, the cell mediated immune response observed didn't show any significant rise in any of the treatment groups.
conclusionCalves administered the intranasal nanoparticle vaccine induced significantly greater mucosal IgA responses, compared to the other treatment groups. This suggests an enhanced, sustained mucosal-based immunological response to the BPI3V nanoparticle vaccine in the face of pre-existing antibodies to BPI3V, which are encouraging and potentially useful characteristics of a candidate vaccine. However, ability of nanoparticle vaccine in eliciting cell mediated immune response needs further investigation. More sustained local mucosal immunity induced by nanoparticle vaccine has obvious potential if it translates into enhanced protective immunity in the face of virus outbreak.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.